Results 151 to 160 of about 6,454 (219)

Exploring the Potential Link Between Tirzepatide and Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION): Evidence from FAERS and Google Trends. [PDF]

Hosp Pharm
Castellana E, Chiappetta MR.
europepmc   +1 more source

Incretin hormone agonists as promising antiobesity drugs - review of literature [PDF]

The aim of this work is to draw attention to the recently growing problem of obesity and complications related to it. Dietary recommendations and recommendations regarding physical activity turned out not to show satisfactory effects in patients with ...
Dardzińska, Nicol, Dziedziak, Marta, Grzegorczyk, Aleksandra, Hopej, Natalia, Korus, Justyna   +4 more
core   +1 more source

Efficacy and safety of glucagon‐like peptide 1 receptor agonists across all health outcomes in type 2 diabetes: An umbrella review and evidence map of randomised controlled trials

Diabetes, Obesity and Metabolism, Volume 28, Issue 2, Page 1136-1149, February 2026.
Abstract Aim Glucagon‐like peptide 1 receptor agonists (GLP‐1RAs) have been established as effective treatments for type 2 diabetes, offering benefits beyond glycaemic control; however, their associations across multiple health outcomes remain insufficiently assessed.
Dongjin Yeo, Yeona Jo, Jinyoung Jeong, Yi Deun Jeong, Ho Geol Woo, Yejun Son, Sunyoung Kim, Sang Youl Rhee, Dong Keon Yon   +8 more
wiley   +1 more source

A metabolic comparison of GIPR agonism versus GIPR antagonism in male mice

Diabetes, Obesity and Metabolism, Volume 28, Issue 2, Page 1160-1167, February 2026.
Abstract Aims Targeting the glucose dependent insulinotropic polypeptide receptor (GIPR) is of growing interest for treating type 2 diabetes and obesity, though the optimal approach remains unclear. Both GIPR agonism and antagonism, respectively, incorporated into drugs like tirzepatide and maridebart cafraglutide, have paradoxically both shown ...
Iona Davies, Alexandra Turland, Hanh Duyen Tran, Carissa Wong, Olivier Cahn, Cecilia Dunsterville, Yichang Sun, Yilin Xiao, Kevin G. Murphy, Stephen R. Bloom, Ben Jones, Tricia M. M. Tan   +11 more
wiley   +1 more source

Tirzepatide reduces alcohol drinking and relapse-like behaviours in rodents. [PDF]

EBioMedicine
Edvardsson CE, Adermark L, Gottlieb S, Alfreji S, Emous TA, Gouda Y, Thorsell A, Vujičić M, Aranäs C, Benrick A, Wernstedt Asterholm I, Lopez MF, Becker HC, Jerlhag E.   +13 more
europepmc   +1 more source

Heart matters: How glucose‐ and lipid‐modulating drugs remodel epicardial adipose tissue accumulation, inflammatory patterns and browning

Diabetes, Obesity and Metabolism, Volume 28, Issue 2, Page 878-894, February 2026.
Abstract Epicardial adipose tissue (EAT) is a metabolically active visceral fat depot located between the myocardium and the visceral pericardium, exerting direct paracrine and vasocrine effects on the heart and coronary vessels. Under physiological conditions, EAT supports myocardial energy metabolism and thermoregulation through fatty acid supply and
Elisabeth Heuboeck, Charnkamal Singh Bhogal, Markus Mandl   +2 more
wiley   +1 more source

The Era for Dual and Triple Receptor Agonists Treating Type 2 Diabetes (T2D) [PDF]

Recent trends for the treatment of type 2 diabetes (T2D) show dual or triple receptor agonists for incretins peptides. They are glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP) and glucagon (GCG).
Bando, Hiroshi
core  

Low immunogenicity of insulin efsitora alfa in participants with type 1 and type 2 diabetes mellitus

Diabetes, Obesity and Metabolism, Volume 28, Issue 2, Page 1350-1358, February 2026.
Abstract Aims To evaluate treatment‐emergent antidrug antibodies (TE ADA) in once‐weekly basal insulin efsitora‐treated participants with type 1 and type 2 diabetes mellitus (T1DM and T2DM) from 5 phase 3 clinical trials and their potential impact on pharmacokinetics, efficacy and safety.
Yun Wang, Sihe Wang, Wei Wang, Xiaoqi Li, Jennifer Leohr, Vitoria Pires, Michelle L. Katz, Christopher J. Child, Robert J. Konrad   +8 more
wiley   +1 more source

A Case of Euglycemic Diabetic Ketoacidosis With Tirzepatide Use and Severe Calorie Restriction. [PDF]

JCEM Case Rep
Raptis D, Theodoropoulos P, Shah MK, Bloomgarden N, Kishore P.   +4 more
europepmc   +1 more source

Safety and effectiveness of tirzepatide during Ramadan fasting: Real‐world evidence from patients with type 2 diabetes in Bangladesh

Diabetes, Obesity and Metabolism, Volume 28, Issue 2, Page 1508-1516, February 2026.
Abstract Aims Ramadan fasting poses challenges for patients with type 2 diabetes mellitus (T2DM) due to increased risks of hypoglycemia and metabolic fluctuations. Tirzepatide, a dual GIP/GLP‐1 receptor agonist, has shown marked efficacy in glycemic control and weight reduction.
Muhammad Hafizur Rahman, Shahjada Selim, Faria Afsana, Md. Azizul Hoque, M. Saifuddin, Md. Shah Alam, Mirza Sharifuzzaman, Mohmmad Abdul Hannan, Md. Nazmul Hasan, A. B. M. Kamrul‐Hasan, Marufa Mustari, Afsar Ahammed   +11 more
wiley   +1 more source